Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses.
about
From bench to bedside: immunotherapy for prostate cancerAndrogen activity and markers of inflammation among men in NHANES IIIAnalysis of immune status after iodine-125 permanent brachytherapy in prostate cancerPreclinical and clinical development of DNA vaccines for prostate cancer.Antibody responses to prostate-associated antigens in patients with prostatitis and prostate cancerIgG responses to tissue-associated antigens as biomarkers of immunological treatment efficacyProstate cancer as a model for tumour immunotherapy.Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer.Phase I trial of tremelimumab in combination with short-term androgen deprivation in patients with PSA-recurrent prostate cancerT cells localized to the androgen-deprived prostate are TH1 and TH17 biased.Androgen Deprivation Therapy and the Incidence of Inflammatory Bowel Disease in Patients With Prostate CancerAndrogen Deprivation Followed by Acute Androgen Stimulation Selectively Sensitizes AR-Positive Prostate Cancer Cells to Ionizing Radiation.Sipuleucel-T: immunotherapy for advanced prostate cancer.A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapyDiffering leukocyte gene expression profiles associated with fatigue in patients with prostate cancer versus chronic fatigue syndrome.Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer.DNA Vaccines for Prostate Cancer.Immune Modulation by Androgen Deprivation and Radiation Therapy: Implications for Prostate Cancer Immunotherapy.Inducible expression of cancer-testis antigens in human prostate cancer.Current and emerging treatment options for castration-resistant prostate cancer: a focus on immunotherapyUnmasking the immune recognition of prostate cancer with CTLA4 blockade.Immune response to sipuleucel-T in prostate cancerThe Rationale for Optimal Combination Therapy With Sipuleucel-T for Patients With Castration-resistant Prostate Cancer.Beyond immune checkpoint blockade: new approaches to targeting host-tumor interactions in prostate cancer: report from the 2014 Coffey-Holden prostate cancer academy meeting.Immunotherapy for prostate cancer: False promises or true hope?Prostate cancer immunotherapy, particularly in combination with androgen deprivation or radiation treatment. Customized pharmacogenomic approaches to overcome immunotherapy cancer resistance.Generation of potent cytotoxic T lymphocytes against castration-resistant prostate cancer cells by dendritic cells loaded with dying allogeneic prostate cancer cells.Enhanced proinflammatory cytokine response to bacterial lipopolysaccharide in the adult male rat after either neonatal or prepubertal ablation of biological testosterone activity.Prostate Cancer Cells Express More Androgen Receptor (AR) Following Androgen Deprivation, Improving Recognition by AR-Specific T Cells.Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancerGenetics and biology of prostate cancerAndrogen deprivation and immunotherapy for the treatment of prostate cancerNo increased risk of psoriasis in patients receiving androgen deprivation therapy for prostate cancer: a 17-year population-based study
P2860
Q26864390-736BD970-5C75-4BB2-8155-CECB6B85A2B3Q33647847-45C211B5-EE6B-4162-8342-0498F6AFAC02Q33707786-57A1DD23-7CC0-4E5B-BC5A-4786B93C7CB4Q33740811-48DA7B17-D7F2-4289-8041-4C86FC2BE73AQ34297813-070691DF-D226-4B99-B3F9-79869CF6F11EQ34443548-E2264851-3E80-4F22-948A-9ABB3863A21AQ34856875-81068D02-66A7-4CEC-BF1A-856DC1154D89Q35641782-A7E5E343-3BFD-4FCA-8EF6-D99A7D5D5330Q35951653-92B120FA-80A9-4427-A8EB-AE1D1101E219Q36905460-9A59D09A-2B79-407B-97A3-FBE7BCD3F2A2Q37056886-8B5BFA96-D2B2-40AA-B105-DA3F0B5E4F51Q37059814-01CD4787-A2BA-4FA4-87E4-0BB3DE2D7B66Q37283724-1781385E-6A95-43FD-96E5-FAFDEE33130FQ37333126-F87A0158-B888-4160-B4CB-92682E654C72Q37359760-F6AA44D6-5663-4EEB-B7DC-C047D8A61D15Q37443603-B18304AC-5FAB-4714-84B3-B5195D94A952Q37604481-F7C8419C-244F-4C51-B4C0-04A0A2BE4990Q37676065-4848DEE9-17BF-4F13-82C7-4FA4637D376BQ37686238-D12D5AC3-ED88-4A45-A81B-31DF5D7CECF3Q37952147-86B43635-7689-4582-8B51-147E87175AA2Q37989393-C03DA210-F141-4B7A-B68F-FD2AE1C7ED98Q38161390-302AE362-61BE-4F0C-80F7-8F77A7842B80Q38261921-E684B4FE-FDFC-46B2-8495-963309BBA6E9Q38264014-182A4B97-A96B-48C7-B8EE-41F1A8257BA4Q38959645-1BAC709D-638B-4662-8C98-ADC7184E3122Q39093352-807B1D4E-188E-4C0E-A56C-381ACB05FDBFQ39249471-161C9F17-CFC5-4AED-94C3-3EA445EEE0DEQ42485736-D917913F-6515-4CBE-B688-7DE8D54E17F0Q47757361-396A81C9-522E-4CC7-B8FB-5DD6C070E1B2Q56892705-68AA2392-3833-478D-BEF2-30CD8E6D0F42Q57106917-A4A6F466-19CD-49F5-B251-5DC7CDBA773FQ57115565-F83B8F75-CD0C-4929-8641-62BDD72BD926Q57490622-1E543E56-C260-4B83-ADE6-F78D6B3C70FE
P2860
Prostate cancer patients on androgen deprivation therapy develop persistent changes in adaptive immune responses.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Prostate cancer patients on an ...... in adaptive immune responses.
@ast
Prostate cancer patients on an ...... in adaptive immune responses.
@en
type
label
Prostate cancer patients on an ...... in adaptive immune responses.
@ast
Prostate cancer patients on an ...... in adaptive immune responses.
@en
prefLabel
Prostate cancer patients on an ...... in adaptive immune responses.
@ast
Prostate cancer patients on an ...... in adaptive immune responses.
@en
P2860
P1433
P1476
Prostate cancer patients on an ...... in adaptive immune responses.
@en
P2093
Douglas G McNeel
Matthew D Morse
P2860
P304
P356
10.1016/J.HUMIMM.2010.02.007
P577
2010-03-05T00:00:00Z